Trial Profile
A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Trifarotene (Primary)
- Indications Acne vulgaris
- Focus Registrational; Therapeutic Use
- Acronyms PERFECT 2
- Sponsors Galderma
- 21 Mar 2023 Results of Pooled Post-hoc analysis , from PERFECT 1 and PERFECT 2 of Safety and Efficacy of Trifarotene 0.005 percent Cream Within the Adolescent Population, presented at the American Academy of Dermatology annual Meeting 2023
- 07 Apr 2020 Results from PERFECT 1 and PERFECT 2 and NCT02189629 assessing safety and efficacy published in the JAMA: the Journal of the American Medical Association
- 08 Jan 2020 According to a Galderma media release, Certara's Simcyp based Simulator was used to support U.S. Food and Drug Administration (FDA) new drug application (NDA) for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.